Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.
THE WINNERS WERE ANNOUNCED AT A COCKTAIL RECEPTION AND AWARDS CEREMONY IN FRANKFURT, GERMANY Source: Shutterstock
Aurobindo has taken home the top prize at the Global Generics & Biosimilars Awards 2019, winning the award for Company of the Year – sponsored by IQVIA – as well as receiving the award for Acquisition of the Year, sponsored by Pharmawise, for its deal to acquire Sandoz' US dermatology and oral-solids businesses.
Now in their sixth year, the awards took place on 5 November in Frankfurt, Germany.
Accord also had a good night, walking away with the awards for Value Added Medicine Initiative of the Year – also sponsored by IQVIA – for its Injexate, Methofill and Metother methotrexate injectors, as well as the award for Legal Strategy of the Year for its UK approach to intellectual property around Lumigan (bimatoprost) 0.01%. (Also see "Accord And Aspire Beat Bimatoprost Patent In The UK" - Generics Bulletin, 8 May, 2019.)
The three regional Company of the Year awards for the EMEA, Americas and Asia-Pacific regions went to Stada, Eurofarma and Beximco Pharma respectively.
Zentiva’s Haggar Is Leader Of The Year
Zentiva CEO Nick Haggar won the award for Leader of the Year – sponsored by Pharmacloud – with a string of deals in quick succession this year standing as testament to his vision for the company. (Also see "Zentiva Snaps Up Alvogen’s CEE Operations" - Generics Bulletin, 25 Oct, 2019.)
And blazing a trail with its Chinese approval and launch of biosimilar rituximab (Also see "Chinese Biosimilar Boom Is Heralded By First Approval" - Generics Bulletin, 28 Feb, 2019.) enabled Shanghai Henlius Biotech to secure our Biosimilar Initiative of the Year Award.
Rephine’s focus on compliance, quality and good manufacturing practice helped the firm to secure the award for Industry Partner of the Year, sponsored by Aurobindo.
Meanwhile, Sandoz’ landmark approval under China’s Quality Consistency Evaluation (QCE) system (Also see "Sandoz’ Unique Chinese Approval Paves The Way For Tender Access" - Generics Bulletin, 10 May, 2019.) gave it the edge in a competitive category this year, making the firm the worthy winner of our award for Regulatory Achievement of the Year, sponsored by Piramal.
PharmEvo’s orodispersible powder with micro encapsulated iron secured the highest scores from our judges of the Business Development of the Year Award, sponsored by West Pharma.
Dr Reddy’s walked away with the award for API Supplier of the Year, while Teva won the award for Corporate Social Responsibility Initiative of the Year, sponsored by International Health Partners. Insud Pharma sponsored event literature.
Generics Bulletin and Informa Pharma Intelligence are delighted to congratulate the worthy winners of the Global Generics & Biosimilars Awards 2019. The winners, shortlisted candidates, and all entries to the Awards are great examples of the dedication and commitment that the generics, biosimilars and value-added medicines industries demonstrate every day in making more affordable treatments more accessible to ever more people around the world.
To enquire about sponsorship opportunities for the Global Generics & Biosimilars Awards 2020, please e-mail email@example.com
To request tickets to attend the Global Generics & Biosimilars Awards 2020, and for any further details, please e-mail firstname.lastname@example.org
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: